PhRMA Statement on CMS' Initial Price-Setting 'Offer' to Biopharmaceutical Companies
June 26, 2024
June 26, 2024
WASHINGTON, June 26 (TNSres) -- The Pharmaceutical Research and Manufacturers of America issued the following statement on June 25, 2024:
* * *
IRA's drug pricing provisions may undermine new out-of-pocket cap in Medicare Part D
* * *
According to a new analysis from Milliman commissioned by PhRMA, the drug pricing provisions of the Inflation Reduction Act (IRA) could result in 3.5 million Medicare Part D beneficiaries facing higher out-of-pock . . .
* * *
IRA's drug pricing provisions may undermine new out-of-pocket cap in Medicare Part D
* * *
According to a new analysis from Milliman commissioned by PhRMA, the drug pricing provisions of the Inflation Reduction Act (IRA) could result in 3.5 million Medicare Part D beneficiaries facing higher out-of-pock . . .